Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2013

01-08-2013 | Research Article

CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression

Authors: Bao-Sheng Wang, Zhen Liu, Wei-Xue Xu, Shao-Long Sun

Published in: Tumor Biology | Issue 4/2013

Login to get access

Abstract

CYP3A5 is a cytochrome P450 superfamily member which is involved in the metabolism of drugs, steroid hormones, and other xenobiotics. Emerging evidences suggest that CYP3A5*3 (rs776746 A>G) polymorphism may play a role in the etiology of carcinogenesis and affect an individual's susceptibility to cancer in humans, but individually published studies showed inconclusive results. This meta-analysis aimed to derive a more accurate estimation of the correlation between CYP3A5*3 polymorphism and cancer risk. A literature search of PubMed, Embase, Web of Science, and China BioMedicine databases was conducted on articles published before January 1, 2013. Seventeen case–control studies were included with a total of 7,458 cancer patients and 7,166 healthy controls. The meta-analysis results showed that CYP3A5*3 polymorphism may increase the risk of cancer, especially in acute leukemia, chronic leukemia, and colorectal cancer. However, no statistically significant associations were found in prostate cancer, liver cancer, and other cancers. Further subgroup analysis by ethnicity indicated that CYP3A5*3 polymorphism was associated with an increased risk of cancer among Asian and Caucasian populations, but not among African populations. In conclusion, the current meta-analysis suggests that CYP3A5*3 polymorphism may play an important role in the development of acute and chronic leukemia and colorectal cancer, especially among Asian and Caucasian populations.
Literature
1.
2.
Are C, Rajaram S, Are M, Raj H, Anderson BO, Chaluvarya Swamy R, et al. A review of global cancer burden: trends, challenges, strategies, and a role for surgeons. J Surg Oncol. 2013;107:221–6.PubMedCrossRef
3.
Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K, Fraumeni Jr JF. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta. 2001;1471:C1–10.PubMed
4.
Fontham ET, Thun MJ, Ward E, Portier KM, Balch AJ, Delancey JO, et al. American Cancer Society perspectives on environmental factors and cancer. CA Cancer J Clin. 2009;59:343–51.PubMedCrossRef
5.
Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4:177–83.PubMedCrossRef
6.
Futreal PA, Kasprzyk A, Birney E, Mullikin JC, Wooster R, Stratton MR. Cancer and genomics. Nature. 2001;409:850–2.PubMedCrossRef
7.
Bartsch H, Dally H, Popanda O, Risch A, Schmezer P. Genetic risk profiles for cancer susceptibility and therapy response. Recent Results in Cancer Research Fortschritte der Krebsforschung Progres dans les Recherches sur le. Cancer. 2007;174:19–36.
8.
Nebert DW, Dalton TP. The role of cytochrome p450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006;6:947–60.PubMedCrossRef
9.
Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics. 2001;11:111–21.PubMedCrossRef
10.
Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics. 2003;13:461–72.PubMedCrossRef
11.
12.
Dandara C, Ballo R, Parker MI. CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett. 2005;225:275–82.PubMedCrossRef
13.
Li ZH, Tsuchiya N, Narita S, Inoue T, Horikawa Y, Kakinuma H, et al. CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population. Cancer Lett. 2005;225:237–43.CrossRef
14.
Vaarala MH, Mattila H, Ohtonen P, Tammela TL, Paavonen TK, Schleutker J. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. Int J Cancer J Int Cancer. 2008;122:2511–6.CrossRef
15.
Sailaja K, Rao DN, Rao DR, Vishnupriya S. Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients. Asian Pac J Cancer Prev: APJCP. 2010;11:781–4.PubMed
16.
Bethke L, Webb E, Sellick G, Rudd M, Penegar S, Withey L, et al. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC Cancer. 2007;7:123.PubMedCrossRef
17.
Gervasini G, Garcia-Martin E, Ladero JM, Pizarro R, Sastre J, Martinez C, et al. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer. 2007;7:118.PubMedCrossRef
18.
Petrova DT, Yaramov N, Toshev S, Nedeva P, Maslyankov S, von Ahsen N, et al. Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls. Onkologie. 2007;30:559–63.PubMedCrossRef
19.
Bajpai P, Tripathi AK, Agrawal D. Genetic polymorphism of CYP3A5 in Indian chronic myeloid leukemia patients. Mol Cell Biochem. 2010;336:49–54.PubMedCrossRef
20.
Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, et al. Strengthening the reporting of observational studies in epidemiology–molecular epidemiology (STROBE-ME): an extension of the STROBE statement. PLoS Med. 2011;8:e1001117.PubMedCrossRef
21.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef
22.
Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28:123–37.PubMedCrossRef
23.
Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 2008;336:1413–5.PubMedCrossRef
24.
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–80.PubMedCrossRef
25.
Huang Z, Cai YH, Chen JN, He HL, Li J, Lu J. Association between CYP3A5 gene polymorphisms and childhood acute leukemia. Chin J Pediatr. 2007;45:546–8.
26.
Lu HX, Feng ZB, Feng XL. A case–control study on the association of hepatocellular carcinoma with genetic polymorphisms of CYP3A5 in a highly aflatoxin b1 contaminated guangxi area. Chin J Hepatol. 2007;15:705–6.
27.
Azarpira N, Ashraf MJ, Khademi B, Darai M, Hakimzadeh A, Abedi E. Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma. Mol Biol Rep. 2011;38:5443–8.PubMedCrossRef
28.
Borst L, Wallerek S, Dalhoff K, Rasmussen KK, Wesenberg F, Wehner PS, et al. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia. Eur J Haematol. 2011;86:477–83.PubMedCrossRef
29.
Kristiansen W, Haugen TB, Witczak O, Andersen JM, Fossa SD, Aschim EL. CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility. Int J Androl. 2011;34:77–83.PubMedCrossRef
30.
Lim JS, Chen XA, Singh O, Yap YS, Ng RC, Wong NS, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011;71:737–50.PubMedCrossRef
31.
Rao DN, Manjula G, Sailaja K, Surekha D, Raghunadharao D, Rajappa S, et al. Association of CYP3A5*3 polymorphism with development of acute leukemia. Indian J Hum Genet. 2011;17:175–8.PubMedCrossRef
32.
Fernandez P, Zeigler-Johnson CM, Spangler E, van der Merwe A, Jalloh M, Gueye SM, et al. Androgen metabolism gene polymorphisms, associations with prostate cancer risk and pathological characteristics: a comparative analysis between south African and Senegalese men. Prostate Cancer. 2012;2012:798634.PubMedCrossRef
33.
Silveira VS, Canalle R, Scrideli CA, Queiroz RG, Lopes LF, Tone LG. CYP3A5 and NAT2 gene polymorphisms: role in childhood acute lymphoblastic leukemia risk and treatment outcome. Mol Cell Biochem. 2012;364:217–23.PubMedCrossRef
34.
Willrich MA, Hirata MH, Hirata RD. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics. 2009;10:1017–24.PubMedCrossRef
35.
Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54:1271–94.PubMedCrossRef
36.
Roco A, Quinones L, Agundez JA, Garcia-Martin E, Squicciarini V, Miranda C, et al. Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the Chilean population: comparison with Caucasian and Asian populations. Front Genet. 2012;3:229.PubMedCrossRef
37.
Rosenthal R, DiMatteo MR. Meta-analysis: recent developments in quantitative methods for literature reviews. Annu Rev Psychol. 2001;52:59–82.PubMedCrossRef
38.
Rendic S, Guengerich FP. Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol. 2012;25:1316–83.PubMedCrossRef
39.
Walsky RL, Obach RS, Hyland R, Kang P, Zhou S, West M, et al. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos: Biol Fate Chem. 2012;40:1686–97.CrossRef
40.
Ioannidis JP, Lau J. Pooling research results: benefits and limitations of meta-analysis. Jt Comm J Qual Improv. 1999;25:462–9.PubMed
Metadata
Title
CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression
Authors
Bao-Sheng Wang
Zhen Liu
Wei-Xue Xu
Shao-Long Sun
Publication date
01-08-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0783-2

Other articles of this Issue 4/2013

Tumor Biology 4/2013 Go to the issue

Research Article

Imaging and therapy of hSSTR2-transfected tumors using radiolabeled somatostatin analogs

Research Article

Shugoshin1 enhances multidrug resistance of gastric cancer cells by regulating MRP1, Bcl-2, and Bax genes

Erratum

Erratum to: Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis—correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met

Research Article

Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer

Research Article

Glutathione S-transferase M1 null genotype contributes to increased risk of esophageal carcinoma in Chinese population

Review

Crosstalk between breast cancer stem cells and metastatic niche: emerging molecular metastasis pathway?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits